DrKKD’s Activity

Tue Nov 5

NL

Article

DrKKD published an article 4:16 PM

Is This Regeneron's Biggest Opportunity?

Alirocumab represents a long-term opportunity to Regeneron and its partner Sanofi.

Wed Oct 23

NL

Article

DrKKD published an article 1:23 PM

Why This Acquisition Makes Sense

Mesoblast's acquisition of Osiris Therapeutics' MSC business makes strategic sense.

Thu Oct 10

NL

Article

DrKKD published an article 6:48 PM

A Solid Health Care Stock to Watch?

With its solid business, Baxter International is a stock to watch for investors looking for dividends.

Fri Oct 4

NL

Article

DrKKD published an article 12:00 AM

This Company Is Focused on Delivering Value to Patients and Shareholders

Dyax is looking to capitalize on its unique phage display technology (companies discussed in this article include VPHM, SHPG, DYAX).

Thu Oct 3

NL

Article

DrKKD published an article 11:00 AM

Why AbbVie's Global Alliance With Galapagos Is Good News for Investors

AbbVie's global alliance with Galapagos will further boost the company's financial performance.

Mon Sep 30

NL

Article

DrKKD published an article 10:54 AM

3 Stocks to Watch in the Urology Devices Market

How Endo Health is performing in the urology devices market.

NL

Article

DrKKD published an article 10:26 AM

Abraxane's Approval for Pancreatic Cancer Is a Major Milestone for Celgene

Abraxane approval for pancreatic cancer will boost Celgene's top-line.

Mon Sep 23

NL

Article

DrKKD published an article 11:13 AM

Why You Should Get Excited About This Health Care Company

Steris offers steady growth in multiple markets.

NL

Article

DrKKD published an article 10:06 AM

Why Teva's Generic Version of Xeloda Has Significant Potential

Teva's generic Xeloda may be a game changer for the company.

Fri Sep 20

NL

Article

DrKKD published an article 4:28 PM

An Excellent Investment in the Biotech Space?

Exelixis might be a stock to watch.

NL

Article

DrKKD published an article 10:19 AM

4 Reasons to Buy This Biotechnology Stock

Isis has many positives for investors.

Mon Sep 16

NL

Article

DrKKD published an article 4:54 PM

Alnylam's Biggest Opportunities

Alnylam Pharmaceuticals is an emerging leader in a new gene-based therapy.

Thu Sep 12

NL

Article

DrKKD published an article 9:49 AM

Time to Bet on This Biotech Spinoff?

Theravance is not too healthy right now.

Wed Sep 11

NL

Article

DrKKD published an article 4:06 PM

Will History Repeat for Inhaled Insulin?

Mannkind's Afrezza is better than Exubera, but by how much?

NL

Article

DrKKD published an article 1:57 PM

3 Justifications for the High Cost of Gattex

Gattex may seem pricey, but it will still sell.

NL

Article

DrKKD published an article 1:53 PM

What Does Roche's Inovio Deal Mean for Investors?

Inovio is not for the short-sighted.

NL

Article

DrKKD published an article 11:18 AM

Cheers and Jeers for Amgen's Pipeline

Amgen's heart drug may be revived, despite failure, all puns intended.

Tue Sep 10

NL

Article

DrKKD published an article 2:26 PM

Everyone Wants a Piece of This Mega-Blockbuster

The fight for sofosbuvir.

Mon Sep 9

NL

Article

DrKKD published an article 1:18 PM

Outsourcing Your Laboratory

Covance is doing well with its contract research business.

NL

Article

DrKKD published an article 12:34 PM

A Growth Story in Molecular Diagnostics

Cepheid is benefiting from the new trends in MDx.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75012
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to DrKKD’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show DrKKD’s 10 Latest Posts